Why the study?
Does adding niacin, fibrates, or n-3 fatty acids to statin therapy reduce residual cardiovascular risk in high-risk patients with atherogenic dyslipidaemia?
Does adding niacin, fibrates, or n-3 fatty acids to statin therapy reduce residual cardiovascular risk in high-risk patients with atherogenic dyslipidaemia?
Adding non-statin therapies like fenofibrate or n-3 fatty acids to statins may help address residual cardiovascular risk in patients with atherogenic dyslipidaemia, though robust clinical trial evidence remains limited.
May support fenofibrate or low-dose n-3 addition in select patients; leaves open confirmatory RCTs for residual risk reduction.
Although statins significantly decrease the incidence of cardiovascular disease (CVD), residual CVD risk remains high. This may partly be due to uncorrected atherogenic dyslipidaemia. The driving force behind atherogenic dyslipidaemia is hypertriglyceridaemia, which results from hepatic oversecretion and/or hypocatabolism of triglyceride-rich lipoproteins, and is typical of type 2 diabetes and metabolic syndrome. Persistent atherogenic dyslipidaemia in patients treated with a statin according to low-density lipoprotein-cholesterol goals may be corrected with niacin, fibrates or n-3 fatty acids. Clinical trial evidence to inform best practice is limited, but new data support adding fenofibrate to a statin. A consistent feature of fibrate clinical trials is the specific benefit of these agents in dyslipidaemic patients and the improvement in diabetic retinopathy with fenofibrate. Ongoing clinical trials may provide good evidence for adding niacin to a statin. Low-dose n-3 fatty acids could be used routinely after a myocardial infarction, but the value of higher doses of n-3 fatty acids in reducing CVD risk remains to be demonstrated.
No takes yet. Share an insight, caveat, or question.
Watts et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: